Octaplasma Plasma collection is performed using a process called plasmapheresis, which involves the separation of plasma from other blood components using a centrifuge. The plasma is then collected into a sterile collection bag, which is stored at 1-6°C until it is transported to the manufacturing facility. Plasma preparation involves the pooling of plasma from at least 1,000 donors. The pooled plasma is then treated with a solvent/detergent mixture, which inactivates enveloped viruses and lipid-enveloped bacteria. The solvent/detergent treatment also removes plasma proteins that may interfere with the coagulation process. Filtration is the next step in the manufacturing process, which involves the removal of solvent/detergent and other impurities from the plasma. The plasma is passed through a series of filters, including nanofiltration and depth filtration, which remove viruses, bacteria, and other impurities. Final product testing is the last step in the manufacturing process, which involves the testing of Octaplasma for the presence of infectious agents, including HIV, hepatitis B and C, syphilis, and West Nile virus. The final product is also tested for the concentration of coagulation factors, including Factor VIII, Factor IX, and von Willebrand factor. Octaplasma is manufactured by Octapharma, a Swiss-based pharmaceutical company specializing in the development, production, and sale of human proteins from human plasma and human cell lines. The manufacturing process for Octaplasma involves several steps, including donor selection, plasma collection, plasma preparation, solvent/detergent treatment, filtration, and final product testing. Final product testing is the last step in the manufacturing process, which involves the testing of Octaplasma for the presence of infectious agents, including HIV, hepatitis B and C, syphilis, and West Nile virus. The final product is also tested for the concentration of coagulation factors, including Factor VIII, Factor IX, and von Willebrand factor. Octaplasma is administered intravenously, and the dosage is based on the patient's weight and the desired level of coagulation factor replacement. The half-life of coagulation factors in Octaplasma is approximately 6-8 hours, which means that the product needs to be administered every 8-12 hours to maintain adequate coagulation factor levels. Octaplasma is a safe and effective plasma product, and it has been used in clinical practice for over 20 years. The product has been shown to be effective in the treatment of congenital and acquired coagulation factor deficiencies, and it has also been used in patients undergoing plasma exchange. In summary, Octaplasma is a pooled, solvent/detergent-treated, plasma product derived from the pooled plasma of at least 1,000 donors. It is a sterile, apyrogenic, frozen solution of human plasma proteins, which contains labile coagulation factors in concentrations that approximate those in fresh frozen plasma. Octaplasma is used for replacement therapy in patients with congenital or acquired deficiencies of coagulation factors, and in patients undergoing plasma exchange. The manufacturing process for Octaplasma involves several steps, including donor selection, plasma collection, plasma preparation, solvent/detergent treatment, filtration, and final product testing. Octaplasma is a safe and effective plasma product, and it has been used in clinical practice for over 20 years.
Flight 1629, operated by Southwest Airlines, is a regularly scheduled flight between Baltimore/Washington International Thurgood Marshall Airport (BWI) and Phoenix Sky Harbor International Airport (PHX). The flight typically uses a Boeing 737 aircraft and covers a distance of approximately 2,000 miles, taking around 5 hours to complete.